Methods Patients with histologically confirmed H-SIL and/or VIN 2–3 will be treated with Pembrolizumab 200 mg flat dose every 3 weeks for 5 cycles. Within 4 weeks from the last Pembrolizumab administration patients will be submitted to surgical conization (either cold knife conization or LEEP) and/or partial or radical vulvectomy. During the screening phase patients will receive blood and stool specimen’s collection. Genotyping for HPV will be performed at baseline, surgery and at safety follow up visit.

Results Trial in progress: there are no available results at the time of submission.

Conclusions Trial in progress: there are no available conclusions at the time of submission.

Results Trial in progress: there are no available results/conclusions at the time of submission.

Conclusions N/A

Surgical films

Surgical session: Video highlights

FF001/#573 NEAR-INFRARED ANGIOGRAPHY FOR ASSESSMENT OF RECTOSIGMOID ANASTOMOSES IN GYNECOLOGIC SURGERY
Tiffany Sia*, Oliver Zivanovic, Emeline Aviki. Memorial Sloan Kettering Cancer Center, Surgery, New York, New York, USA
10.1136/ijgc-2022-igcs.553

Introduction Rectosigmoid resections are frequently needed to achieve complete disease clearance during surgery for ovarian cancer. A severe complication from rectosigmoid resections is anastomotic leakage. Near infrared angiography (NIR) has been introduced to assess perfusion of vascular pedicles. Given the interest in usage of NIR to evaluate perfusion during rectosigmoid anastomoses, we have put together an instructional video demonstrating the setup and usage of this technology.

Description Intraoperative setup for NIR will require a PINPOINT endoscopic fluorescence imaging system including a 10 mm laparoscope, a PINPOINT rigid scope introducer, and 23 mg of indocyanine green (ICG) dye. After the segment of colon with disease is isolated and divided, perfusion is tested in the proximal limb by injecting 5 mL of the reconstituted ICG intravenously, allowing one minute for the dye to mobilize, and visualizing the bowel with the 10 mm laparoscope. A perfusion defect is identified, and the decision is made to further resect the segment of bowel without perfusion. After this step, the trimmed proximal limb is brought down to the pelvis and anastomosed with the distal limb. Perfusion is tested after anastomosis by bringing placing the PINPOINT rigid scope introducer over the 10 mm laparoscope and introducing the scope through the anus until the anastomotic ring is identified. 5 mL of ICG is re-injected. Perfusion is tested again and found to be adequate.

Conclusion/Implications Assessment of rectosigmoid anastomoses performed for gynecologic surgery using NIR with ICG is feasible, can be performed without the need for numerous additional instruments.

TP043/#1565 PHASE II ACTIVITY TRIAL OF HIGH DOSE RADIATION AND CHEMOSENSITIZATION IN PATIENTS WITH MACROMETASTATIC LYMPH NODE SPREAD AFTER SENTINEL NODE BIOPSY IN VULVAR CANCER: GRONINGEN INTERNATIONAL STUDY ON SENTINEL NODES IN VULVAR CANCER III (GROINSS-V III/NRG-GY024)
1Lilian Gien*, 2Brian Slomovitz, 3Mario Leitao, 4Ate Gj Van Der Zee, 5Carien Creutzberg, 6An KI Reynolds, 7Petronella Witteveen, 8Diandra Ayala-Peacock, 9Iyoti Mayadev, 10Charles Leath lii, 11Maake Oonk. 1Sunnybrook Odette Cancer Center, Division of Gynecologic Oncology, Toronto, Canada; 2Mount Sinai Medical Center, Department of Obstetrics and Gynecology, Miami, USA; 3Memorial Sloan Kettering Cancer Center, Division of Gynecologic Oncology, New York, USA; 4University Medical Center Groningen, Gynecologic Oncology, Groningen, Netherlands; 5Leiden University, Radiation Oncology, Leiden, Netherlands; 6University Medical Center Groningen, Medical Oncology, Groningen, Netherlands; 7University Medical Center Utrecht, Medical Oncology, Umc Utrecht Cancer Center, Utrecht, Netherlands; 8Duke Cancer Institute, Radiation Oncology, Raleigh, USA; 9UC Davis Comprehensive Cancer Center, Radiation Oncology, Sacramento, USA; 10The University of Alabama at Birmingham, Division of Gynecologic Oncology, Birmingham, USA; 11University Medical Center Groningen, Obstetrics and Gynecology, Groningen, Netherlands
10.1136/ijgc-2022-igcs.552

Objectives To investigate the safety of replacing inguinofemoral lymphadenectomy (IFL) by chemoradiation in early-stage vulvar cancer patients with a macrometastasis (>2 mm) and/or extracapsular extension in the sentinel node (SN).

Methods This is an international multicenter single-arm phase II prospective clinical trial. Primary endpoint is groin recurrence rate in the first two years after primary treatment. Secondary endpoints are short and long-term morbidity associated with the SN procedure and chemoradiation and quality of life as measured by EORTC-QLQc30. Patients with invasive (>1 mm) squamous cell carcinoma of the vulva, stage T1, tumor size <4 cm diameter and no suspicious lymph nodes by imaging will proceed with SN detection. Institutions enrolling patients must demonstrate prior surgical experience with the submission of at least 10 successfully completed SN cases in vulvar cancer. Patients with SN metastases > 2 mm and/or with extracapsular extension or those with >1 SN with micrometastases are eligible. Treatment consists of chemoradiation with a dose of 56 Gy to the groin combined with weekly cisplatin 40 mg/m2 IV on days 1, 8, 15, 21 and 29 of radiotherapy. One hundred and fifty-seven patients in Europe, United States and Canada will be enrolled. The study includes continuous monitoring of groin recurrences with stopping rules. Results of this trial may be practice changing and eliminate the need for IFL in all women with clinically early stage vulvar cancer. The study is currently open for enrollment.

NCT05076942.